Revive Therapeutics Ltd (RVVTF)

[Gatorca]

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for #Bucillamine in #COVID19
FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for #Bucillamine in #COVID19

FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization

Learn more: https://t.co/m0BhYm3fp3$RVV $RVVTF pic.twitter.com/ZpAivL5Tzk

— Revive Therapeutics (CSE: RVV, US: RVVTF) Official (@Revive_RVV) June 24, 2022

https://revivethera.com/2022/06/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-10/